Observational Antiretroviral Studies In Southern Africa (OASIS) Collaboration

Information

  • Research Project
  • 8134684
  • ApplicationId
    8134684
  • Core Project Number
    U01AI069924
  • Full Project Number
    3U01AI069924-05S1
  • Serial Number
    69924
  • FOA Number
    RFA-AI-05-014
  • Sub Project Id
  • Project Start Date
    7/1/2006 - 18 years ago
  • Project End Date
    6/30/2011 - 13 years ago
  • Program Officer Name
    ZIMAND, LORI B.
  • Budget Start Date
    9/8/2010 - 14 years ago
  • Budget End Date
    6/30/2011 - 13 years ago
  • Fiscal Year
    2010
  • Support Year
    5
  • Suffix
    S1
  • Award Notice Date
    9/8/2010 - 14 years ago
Organizations

Observational Antiretroviral Studies In Southern Africa (OASIS) Collaboration

DESCRIPTION (provided by applicant): Rationale: Southern Africa is where almost 30% of the approximately 40 million HIV-infected people in the world live, in an area estimated to have 2% of the global population. While an estimated two million men, women, and children are yet in urgent need of antiretroviral treatment in this region, close to 200,000 individuals are now believed by the World Health Organization to be receiving treatment. Answers are urgently needed to clinical and operational research questions regarding the most effective implementation and monitoring of wide-scale antiretroviral treatment delivery. Specific Aims: 1) To measure the effectiveness of antiretroviral therapy in southern Africa, and to describe factors that influence outcomes;2) To improve the prognosis of people living with HIV and AIDS eligible for or initiating highly active antiretroviral treatment in southern Africa through timely and operative regional epidemiological evaluations;and 3) To increase the capacity for delivering antiretroviral therapy in this region by increasing the capacity for monitoring exposures and outcomes at the individual and population levels. Research Objectives: 1) To describe issues related to the provision of health care to children and adults in southern Africa, with a focus on the delivery of ART, waiting times and program level influences on survival and other outcomes, including losses to follow up;2) To describe antiretroviral treatment issues in adults (including pregnant women) and children, with an emphasis on the monitoring of treatment response and prognostic factors, including exposure to drugs to prevent mother to child transmission of HIV, and adverse events associated with antiretroviral treatment;and 3) To describe issues related to important complications of HIV infection and antiretroviral therapy use, with a focus on tuberculosis, the immune reconstitution and inflammatory syndrome, and prophylaxis against life-threatening opportunistic infections. Research Design and Methods: The OASIS Collaboration includes 17 clinics and clinical cohorts in 6 countries in the region, involving 35,070 HIV-1 infected adults and children. We will use innovative and state-of-the-art statistical approaches to analyze data from this observational cohort study, including techniques which account for the longitudinal and hierarchical structure of the data. An operational structure is proposed that emphasizes the long-term collaborative and capacity-building approach of the collaboration.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    U01
  • Administering IC
    AI
  • Application Type
    3
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    413807
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    999
  • Ed Inst. Type
  • Funding ICs
    NIAID:413807\
  • Funding Mechanism
    Research Projects
  • Study Section
    ZAI1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    UNIVERSITY OF BERN
  • Organization Department
  • Organization DUNS
    488977901
  • Organization City
    BERN
  • Organization State
  • Organization Country
    SWITZERLAND
  • Organization Zip Code
    3012
  • Organization District
    SWITZERLAND